ArticleIn vivo (Athens, Greece)

Nivolumab Rechallenge After Immune-related Adverse Events in Patients With Unresectable Advanced or Recurrent Esophageal Cancer.

Kohdai Ueno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.